Navigate Kuwait's MOH pharmaceutical registration requirements with confidence. Medwisdom Lifescience delivers end-to-end dossier preparation, local agent coordination, and full compliance support under GCC and eCTD guidelines.
Under Kuwait's Pharmacy Law and Ministerial Decree No. 361 of 2019, any pharmaceutical product must be registered with the Pharmaceutical and Herbal Medicines Registration and Control Administration (PHMRCA) under the Ministry of Health (MOH) before it can enter the Kuwaiti market.
The registration framework applies to all product categories — including new chemical entities, generics, biologics, and biosimilars. Every foreign pharmaceutical product must be represented by a licensed local agent who is responsible for submitting the required documentation and maintaining ongoing compliance.
All pharmaceutical registration dossiers must be structured in accordance with the Common Technical Document (eCTD) format as per GCC guidelines.
Marketing Authorization Holders (MAHs) are required to provide a legalized letter of appointment granting exclusivity to their local agent in Kuwait. The registration certificate must be renewed every five years, with renewal applications submitted up to six months before certificate expiry.
Start Your Registration →Medwisdom supports registration across all pharmaceutical product categories recognized under Kuwait MOH guidelines.
Full eCTD dossier preparation and MOH submission for new chemical entities (NCEs) and innovative formulations requiring complete safety, efficacy, and quality data.
Regulatory dossier preparation for generic drugs, including bioequivalence data compilation and abbreviated submission pathways aligned with GCC requirements.
Registration support for biological products and biosimilars, ensuring compliance with Gulf Health Council (GHC) guidelines and reference authority requirements (EMA/FDA).
Registration and compliance documentation for herbal medicines, over-the-counter health products, and nutraceuticals under Kuwait MOH's dedicated regulatory framework.
A clear, step-by-step overview of how we guide you through the Kuwait pharmaceutical product registration process from initiation to approval.
Our experts conduct a thorough assessment of your product data, identify documentation gaps, and develop a tailored registration strategy aligned with Kuwait MOH requirements and GCC guidelines.
We assist in identifying and appointing a licensed Kuwaiti local agent, and support preparation of the legalized exclusivity appointment letter from the Marketing Authorization Holder (MAH).
Our technical team prepares a complete eCTD dossier covering all five modules — administrative, quality, non-clinical, and clinical data — in accordance with GCC and Kuwait MOH specifications.
We compile and submit the Master File for the manufacturing company, including GMP certificates, manufacturing licenses, site information, and QC documentation from the country of origin.
The completed registration dossier is submitted to the Pharmaceutical and Herbal Medicines Registration and Control Administration (PHMRCA) by the local agent, formally initiating the approval review process.
We manage all MOH queries during the scientific review stage — responding to deficiencies on CMC data, stability studies, and analytical specifications within stipulated timelines.
Upon successful completion of the review, the final approval is endorsed by the PHMRCA authority director, granting Marketing Authorization to commercialize the product in Kuwait.
We provide ongoing compliance support including variation management, pharmacovigilance, label updates, and renewal submissions five years from initial registration date.
The complete document checklist is categorized into three key areas: local agent licensing, manufacturing company registration, and pharmaceutical product dossier.
Kuwait MOH accepts pharmaceutical submissions structured in the internationally recognized Common Technical Document (eCTD) format with GCC-specific requirements in Module 1.
Kuwait-specific admin info, application forms, labelling, certificates, and regional regulatory documents per PHMRCA requirements.
Quality, non-clinical, and clinical overviews and summaries reflecting data in Modules 3, 4, and 5 for reviewer accessibility.
Drug substance & product data: manufacturing process, analytical methods, specifications, stability data, and container closure system.
Pharmacology, pharmacokinetics, and toxicology study reports establishing the non-clinical safety profile of the product.
Clinical study reports, bioequivalence/bioavailability data, and post-market safety data demonstrating product safety and efficacy in humans.
We combine deep regulatory expertise, regional knowledge, and a results-driven approach to ensure your product reaches the Kuwait market efficiently and compliantly.
Our team has in-depth knowledge of Kuwait MOH, GCC Guidelines, and Gulf Health Council (GHC) requirements, ensuring your dossier is compliant and complete from day one.
We handle the entire eCTD dossier — all five modules — prepared by qualified regulatory scientists with hands-on experience in GCC pharmaceutical submissions.
We maintain an established network of licensed Kuwaiti local agents, streamlining the appointment process and reducing the time to market entry significantly.
Our experts monitor and respond to all MOH scientific review queries in a timely and thorough manner, minimizing approval delays and dossier rejections.
From Type IA/IB variations to major post-approval changes, we manage all modification submissions and ensure seamless regulatory maintenance throughout the product lifecycle.
Benefit from a coordinated regulatory strategy across Kuwait, Saudi Arabia, UAE, Qatar, Oman, and Bahrain — maximizing efficiency and reducing duplication of effort.
Common questions about Kuwait pharmaceutical product registration answered by our regulatory experts.
Let Medwisdom's regulatory experts handle your Kuwait MOH drug registration — from dossier preparation to final approval. Get a free assessment today.